New drug iptacopan tested for rare blood disorder in china
NCT ID NCT06931691
First seen Jan 05, 2026 · Last updated May 17, 2026 · Updated 26 times
Summary
This study looks at how well the drug iptacopan works for adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will track changes in hemoglobin levels and other health outcomes over time. About 80 participants in China who have never taken similar drugs will be enrolled. The goal is to see if iptacopan improves disease control and reduces the need for healthcare resources.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGGuangzhou, Guangdong, 510000, China
-
Novartis Investigative Site
RECRUITINGShijiazhuang, Hebei, 050000, China
-
Novartis Investigative Site
RECRUITINGZhengzhou, Henan, 450008, China
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430030, China
-
Novartis Investigative Site
RECRUITINGNanchang, Jiangxi, 330006, China
-
Novartis Investigative Site
RECRUITINGChangchun, Jilin, 130021, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300052, China
-
Novartis Investigative Site
RECRUITINGWuhan, 430022, China
Conditions
Explore the condition pages connected to this study.